Study of Ketamine as an Antidepressant in Major Depressive Disorder
Status:
Unknown status
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Primary Outcome Measures:
Evaluate the changes in neuroimaging and biochemistry measures with ketamine treatment.
Secondary Outcome Measures:
Evaluate the effects of ketamine on depression symptoms, manic symptoms, global change in
psychiatric symptoms, and suicidal ideation.